FGF-8 is involved in bone metastasis of prostate cancer

International Journal of Cancer

Volumn 123, Issue 1, 2008, Pages 22-31

  Valta, Maija P ^a,b   Tuomela, Johanna ^a   Bjartell, Anders ^c   Valve, Eeva ^a   Väänänen, H Kalervo ^a   Härkönen, Pirkko ^a,c  

^a UNIVERSITY OF TURKU   (Finland)

^b HOSPITAL DISTRICT OF SOUTHWEST FINLAND   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Bone metastasis; FGF 8; PC 3 cells; Prostate cancer

Indexed keywords

CATHEPSIN K; FIBROBLAST GROWTH FACTOR 8; OSTEOCALCIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSCLEROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TIBIA; TISSUE MICROARRAY; TUMOR GROWTH;

AGED; ANIMALS; BONE NEOPLASMS; FIBROBLAST GROWTH FACTOR 8; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; TIBIA; UP-REGULATION;

EID: 43949123830     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23422     Document Type: Article

References (53)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
2. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s-6216s.
3. Inoue H, Nishimura K, Oka D, Nakai Y, Shiba M, Tokizane T, Arai Y, Nakayama M, Shimizu K, Takaha N, Nonomura N, Okuyama A. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett 2005;223:121-8.
4. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003;9:2587-97.
5. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 2001;7:2977-83.
6. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006;107:289-98.
7. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-8.
8. Pinski J, Dorff TB. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer 2005;41:932-40.
9. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003;20:171-80.
10. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
11. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24.
12. Heer R, Douglas D, Mathers ME, Robson CN, Leung HY. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004;204:578-86.
13. Jackson RA, Nurcombe V, Cool SM. Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. Gene 2006;379:79-91.
14. Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H, Matsumoto K. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci USA 1992;89:8928-32.
15. Ghosh AK, Shankar DB, Shackleford GM, Wu K, T'Ang A, Miller GJ, Zheng J, Roy-Burman P. Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. Cell Growth Differ 1996;7:1425-34.
16. Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. FGF8 isoform b expression in human prostate cancer. Br J Cancer 2003;88:1432-8.
17. MacArthur CA, Lawshe A, Shankar DB, Heikinheimo M, Shackleford GM. FGF-8 isoforms differ in NIH3T3 cell transforming potential. Cell Growth Differ 1995;6:817-25.
18. Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt RJ, Joyner AL, Mohammadi M. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev 2006;20:185-98.
19. Blunt AG, Lawshe A, Cunningham ML, Seto ML, Ornitz DM, MacArthur CA. Overlapping expression and redundant activation of mesenchymal fibroblast growth factor (FGF) receptors by alternatively spliced FGF-8 ligands. J Biol Chem 1997;272:3733-8.
20. Mattila MM, Harkonen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev 2007;18:257-66.
21. Valve EM, Nevalainen MT, Nurmi MJ, Laato MK, Martikainen PM, Harkonen PL. Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neoplasia lesions and prostate cancer. Lab Invest 2001;81:815-26.
22. Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene 1999;18:2755-61.
23. Tanaka A, Furuya A, Yamasaki M, Hanai N, Kuriki K, Kamiakito T, Kobayashi Y, Yoshida H, Koike M, Fukayama M. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998;58:2053-6.
24. MacArthur CA, Lawshe A, Xu J, Santos-Ocampo S, Heikinheimo M, Chellaiah AT, Ornitz DM. FGF-8 isoforms activate receptor splice forms that are expressed in mesenchymal regions of mouse development. Development 1995;121:3603-13.
25. Loo BM, Salmivirta M. Heparin/Heparan sulfate domains in binding and signaling of fibroblast growth factor 8b. J Biol Chem 2002;277:32616-23.
26. Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res 2000;60:6730-6.
27. Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL. FGF-8b increases angiogenic capacity and tumor growth of androgen-regulated S115 breast cancer cells. Oncogene 2001;20:2791-804.
28. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, Lakkakorpi PT, Harkonen PL. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001;61:4229-37.
29. Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT, Matusik RJ, Miller GJ, Roy-Burman P. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res 2002;62:5096-105.
30. Valta MP, Hentunen T, Qu Q, Valve EM, Harjula A, Seppanen JA, Vaananen HK, Harkonen PL. Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology 2006;147:2171-82.
31. Mattila MM. Fibroblast growth factor 8 and vascular endothelial growth factor C in breast cancer angiogenesis and metastasis, Ph.D. Thesis. Ann Univ Turkuensis, ser. D, vol. D 699, Turku, Finland: Painosalama Oy. ISBN 951-2998-8, 2006.
32. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
33. Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Vaananen HK. Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 2000;46:1751-4.
34. Mai KT, Roustan Delatour NL, Assiri A, Al-Maghrabi H. Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases. Diagn Cytopathol 2007;35:91-5.
35. Sheridan T, Herawi M, Epstein JI, Illei PB. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol 2007;31:1351-5.
36. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003;18:222-30.
37. Pagani F, Francucci CM, Moro L. Markers of bone turnover: biochemical and clinical perspectives. J Endocrinol Invest 2005;28:8-13.
38. Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003;43:309-19.
39. Darby S, Sahadevan K, Khan MM, Robson CN, Leung HY, Gnanapragasam VJ. Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene 2006;25:4122-7.
40. Dorkin T, Bjartell A, Neal D, Leung H. FGF8 expression in prostatic bone and lymph node metastasis. Br J Urol Int 2000;86:392-93 (Abstract).
41. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:Reviews3005.
42. Xu J, Lawshe A, MacArthur CA, Ornitz DM. Genomic structure, mapping, activity and expression of fibroblast growth factor 17. Mech Dev 1999;83:165-78.
43. Condon MS. The role of the stromal microenvironment in prostate cancer. Semin Cancer Biol 2005;15:132-7.
44. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446-65.
45. Hurley M, Marie P, Florkiewicz R. Fibroblast growth factor (FGF) and FGF receptor families in bone. In: Bileziklian J, ed. Principles of bone biology, 2nd edn. New York: Academic Press, 2002.825-51.
46. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987;13:41-9.
47. Ornitz DM. FGF signaling in the developing endochondral skeleton. Cytokine Growth Factor Rev 2005;16:205-13.
48. Gujral A, Burton DW, Terkeltaub R, Deftos LJ. Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence. Cancer Res 2001;61:2282-8.
49. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW, Lang SH. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 2002;86:1136-42.
50. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67:6854-62.
51. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, Schwarz EM, Huard J, Lieberman JR. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006;38:154-66.
52. Shimada N, Ishii T, Imada T, Takaba K, Sasaki Y, Maruyama-Takahashi K, Maekawa-Tokuda Y, Kusaka H, Akinaga S, Tanaka A, Shitara K. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo. Clin Cancer Res 2005;11:3897-904.
53. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 2007;13:2025-44.